Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells

EMBO Journal

Volumn 17, Issue 10, 1998, Pages 2799-2808

  Van Agthoven, Ton ^a,b,c,d   Van Agthoven, Thecla L A ^a,b,c,d   Dekker, Anita ^a,b,c,d   Van Der Spek, Peter J ^a,b,c,d   Vreede, Lilian ^a,b,c,d   Dorssers, Lambert C J ^a,b,c,d  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c Pharming Group NV   (Netherlands)

^d AKZO NOBEL CENTRAL RESEARCH   (Netherlands)

Author keywords

Breast cancer; CDC48; Estrogen receptor; SH2 domain; Tamoxifen

Indexed keywords

ANTIESTROGEN; CELL CYCLE PROTEIN; COMPLEMENTARY DNA; ESTROGEN RECEPTOR; TAMOXIFEN;

AMINO ACID SEQUENCE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GENETICS; CELL CLONE; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG RESISTANCE; GENE FUSION; GENE LOCUS; GENE STRUCTURE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MUTAGENESIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BASE SEQUENCE; BINDING SITES; BREAST NEOPLASMS; CELL FUSION; CLONING, MOLECULAR; DNA, COMPLEMENTARY; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN BIOSYNTHESIS; RECEPTORS, CYCLIC AMP; RNA, MESSENGER; SEQUENCE HOMOLOGY, AMINO ACID; TAMOXIFEN; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0032525138     PISSN: 02614189     EISSN: None     Source Type: Journal    
DOI: 10.1093/emboj/17.10.2799     Document Type: Article

References (51)

1. Acharya, U., Jacobs.R., PetersJ.M., Watson.N., Farquhar.M.G. and Malhotra.V. (1995) The formation of Golgi stacks from vesiculated Golgi membranes requires two distinct fusion events. Cell, 82, 895-904.
2. CailIeau, R., Young.R., Olive.M. and Reeves.W. (1974) Breast tumor cell lines from pleural effusions. J. Natl Cancer Inst., 53, 661-674.
3. Clarke, R. and Brunner,N. (1995) Cross-resistance and molecular mechanisms in antiestrogen resistance. Endocr.-Related Cancer, 2, 59-72.
4. Clarke, R., Dickson.R.B. and Lippman.M.E. (1992) Hormonal aspects of breast cancer. Growth factors, drugs and stromal interactions. Crit. Rev. Oncol. Hematol, 12, 1-23.
5. Clarke, R., Thompson.E.W., Leonessa.R, LippmanJ., McGarvey.M., Frandsen.T.L. and Briinner.N. (1993) Hormone resistance, invasiveness, and metastatic potential in breast cancer. Breast Cancer Res. Treat., 24, 227-239.
6. Clarke, R., Skaar.T., Baumann.K., Leonessa.R, James.M., LippmanJ., Thompson.E.W., Freter.C. and Brunner.N. (1994) Hormonal carcinogenesis in breast cancer: cellular and molecular studies of malignant progression. Breast Cancer Res. Treat., 31, 237-248.
7. Cohen, G.B., Ren.R. and Baltimore.D. (1995) Modular binding domains in signal transduction proteins. Cell, 80, 237-248.
8. Dorssers, L.CJ. and VeldscholteJ. (1997) Identification of a novel breast-cancer-anti-estrogen-resistance (BCAR2) locus by cell-fusionmediated gene transfer in human breast-cancer cells. Int. J. Cancer, 72, 700-705.
9. Dorssers, L.CJ., Van Agthoven.T. and Sieuwerts.A.M. (1991) Genetic mechanisms involved in progression to hormone independence of human breast cancer. In Berns.P.MJ.J., Romijn J.C. and Schroeder.F.H. (eds), Mechanisms of Progression to Hormone-independent Growth of Breast and Prostatic Cancer. Parthenon Publishing Group Ltd, Carnforth, UK, pp. 169-182.
10. Dorssers, L.CJ., Van Agthoven.T., Dekker.A., Van Agthoven.T.L.A. and Kok.E.M. (1993) Induction of antiestrogen resistance in human breast cancer cells by random insertional mutagenesis using defective retroviruses: identification of bear-1, a common integration site. Mol. Endocrinol, 7, 870-878.
11. Early Breast Cancer Trial Collab Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 Randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet, 339, 1-15-71-85.
12. Egerton, M. and Samelson.L.E. (1994) Biochemical characterization of valosin-containing protein, a protein tyrosine kinase substrate in hematopoietic cells. J. Biol. Client., 269, 11435-11441.
13. Egerton, M., Ashe.O.R-, Chen.D., Druker.B.J., Burgess.W.H. and Samelson.L.E. (1992) VCP, the mammalian homolog of cdc48, is tyrosine phosphorylated in response to T cell antigen receptor activation. EMBO J., 11, 3533-3540.
14. Eijdems, E.W.H.M., Borst.R, Jongsma.A.P.M., De Jong.S., De Vries, E.G.E., Van Groenigen.M., Versantvoort.C.H.M., Nieuwint.A.W.M. and Baas.F. (1992) Genetic transfer of non-P-glycoprotein-mediated multidrug resistance (MDR) in somatic cell fusion: dissection of a compound MDR phenotype. Proc. Nail Acad. Sci. USA, 89, 3498-3502.
15. Engel, L.W., Young.N.A., Tralka,T.S., Lippman.M.E., O'Brien.S.J. and Joyce.M.J (1978) Establishment and characterization of three continuous cell lines derived from human breast carcinomas. Cancer Res., 38, 3352-3364.
16. Foekens, J.A., Portengen.H., Look.M.P., Van Putten.W.L.J., Thirion.B., Bontenbal,M. and" KlijnJ.G.M. (1994) Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer. Br. J. Cancer, 70, 1217-1223.
17. FrohIich, K.U., Fries.H.W., RUdiger.M., Erdmann.R., Botstein.D. and Mecke.D. (1991) Yeast cell cycle protein CDC48p shows full-length homology to the mammalian protein VCP and is a member of a protein family involved in secretion, peroxisome formation, and gene expression. J. Cell Biol, 114, 443-453.
18. Frohlich, K.U., Fries.H.W., Peters J.M. and Mecke.D. (1995) The ATPase activity of purified CDC48p from Saccharomyces cerevisiae shows complex dependence on ATP-, ADP-, and NADH- concentrations and is completely inhibited by NEM. Biochim. Biophys. Acta, 1253, 25-32.
19. Habets, G.G.M., Scholtes.E.H.M., Zuydgeest.D., Van der Kammen.R.A., StamJ.C., Bems.A. and CollardJ.G. (1994) Identification of an invasion-inducing gene, Tiam-1, that encodes a protein with homology to GDP-GTP exchangers for Rho-like proteins. Cell, 77, 537-549.
20. Horwitz, K.B. (1993) Mechanisms of hormone resistance in breast cancer. Breast Cancer Res. Treat., 26, 119-130.
21. Jensen, E.V. (1981) Hormone dependency of breast cancer. Cancer (Philadelphia ), 47, 2319-2326.
22. Johnston, S.R.D., Dowsett.M. and Smith.I.E. (1992) Towards a molecular basis for tamoxifen resistance in breast cancer. Ann. Oncol., 3,503-511.
23. Johnston, S.R.D., Saccani-Jotti.G., Smith.I.E., SalterJ., Newby,J., Coppen.M., Ebbs,S.R. and Dowsett.M. (1995) Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifenresistant human breast cancer. Cancer Res., 55, 3331-3338.
24. Jonkers, J. and Berns.A. (1996) Retroviral insertional mutagenesis as a strategy to identify cancer genes. Biochim. Biophys. Acta, 1287,29-57.
25. Jordan, V.C. (1994) Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res. Treat., 31, 41-52.
26. Jordan, V.C. and Murphy.C.S. (1990) Endocrine pharmacology of antiestrogens as antitumor agents. Endocr. Rev., 11, 578-610.
27. King, RJ.B. (1990) Receptors, growth factors and steroid insensitivity of tumours. J. Endocrinol, 124, 179-181.
28. Klijn, J.G.M., Bems,E.M.J.J., Dorssers.L.CJ. and Foekens.J.A. (1994) Molecular markers of resistance to endocrine treatment of breast cancer. In Dickson.R.B. and Lippman.M.E. (eds), Drug and Hormonal Resistance in Breast Cancer, Part II: Cellular and Molecular Mechanisms. Ellis Horwood Ltd, Chichester, pp. 133-168.
29. Kozak, M. ( 1991 ) An analysis of vertebrate mRNA sequences: intimations of translational control. J. Cell Biol., 115, 887-903.
30. Kung, H.J., Boerkoel.C. and Carter.T.H. (1991) Retroviral mutagenesis of cellular oncogenes: a review with insights into the mechanisms of insertional activation. Curr. Top. Microbiol. Immiinol., 171, 1-25.
31. Latterich, M., Frohlich.K.U. and Schekman.R. (1995) Membrane fusion and the cell cycle: Cdc48p participates in the fusion of ER membranes. Cell, 82, 885-893.
32. Mauvais-Jarvis.P., Sitruk-Ware.R. and Kuttenn,F. (1988) The role of hormones in the pathogenesis of benign breast disease. In GrundfestBroniatowski.S. and Esselstyn.C.B. (eds), Controversies in Breast Disease. Marcel Dekker, Inc., New York, pp. 43-61.
33. Mellman, I. (1995) Enigma variations: protein mediators of membrane fusion. Cell, 82, 869-872.
34. Miller, A.D and Rosman.G.J. (1989) Improved retroviral vectors for gene transfer and expression. BioTechniques, 7, 980-990.
35. Miller, S.A., Dykes.D.D. and Polesky.H.F. (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res., 16, 1215-1218.
36. Musgrove, E.A., Hamilton,J.A., Lee.C.S.L., Sweeney.K.J.E., Watts, C.K.W. and Sutherland.R.L. (1993) Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol. Cell. Biol, 13, 3577-3587.
37. Nicholson, S., Halcrow.P., SainsburyJ.R.C., Angus.B., Chambers,?., FamdonJ.R. and Harris.A.L. (1988) Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer. Br. J. Cancer, 58, 810-814.
38. Nicholson, S., Halcrow.P., Farndon.J.R., SainsburyJ.R.C., Chambers,?, and Harris,A.L. (1989) Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet, i, 182-185.
39. Osborne.M.P. (1987) Breast development and anatomy. In HarrisJ.R., Hellman.S., Henderson.I.C. and Kinne.W. (eds), Breast Diseases. Lippincott Company, Philadelphia, PA, pp. 1-14.
40. Osborne.C.K. and Fuqua.S.A.W. (1994) Mechanisms of tamoxifen resistance. Breast Cancer Res. Treat., 32, 49-55.
41. Pawson.T. (1995) Protein modules and signalling networks. Nature, 373, 573-580.
42. Rabouille.C, Levine.T.P., PetersJ.M. and Warren.G. (1995) An NSF-like ATPase, p97, and NSF mediate cisternal regrowth from mitotic Golgi fragments. Cell, 82, 905-914.
43. Rozakis-Adcock,M. et al. (1992) Association of the She and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature, 360, 689-692.
44. Schulte,R.J., Campbell,M.-A., Fischer.W.H. and Sefton.B.M. (1994) Tyrosine phosphorylation of VCP, the mammalian homologue of the Saccharomyces cerevisiae CDC48 protein, is unusually sensitive to stimulation by sodium vanadate and hydrogen peroxide. J. Immunol., 153, 5465-5472.
45. Sieuwerts.A.M., Klijn.J.G.M. and FoekensJ.A. (1997) Assessment of the invasive potential of human gynecological tumor cell lines with the in vitro Boyden chamber assay: influences of the ability of cells to migrate through the filter membrane. Clin. Exp. Metastasis, 15, 53-62.
46. Songyang,Z. et al. (1994) Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav. Mol. Cell. Biol., 14, 2777-2785.
47. Spyratos,F., Andrieu,C., Hacene.K., Chambon.P. and Rio.M.C. (1994) pS2 and response to adjuvant hormone therapy in primary breast cancer. Br. J. Cancer, 69, 394-397.
48. Van Agthoven.T, Van Agthoven.T.L.A., Portengen.H., Foekens,J.A. and Dorssers.L.C.J. (1992) Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. Cancer Res., 52, 5082-5088.
49. Van Agthoven.T., Van Agthoven.T.L.A., Dekker,A., FoekensJ.A. and Dorssers,L.C.J. (1994) Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations. Mol. Endocrinol., 8, 1474-1483.
50. Wolf.D.M. and Fuqua.S.A.W. (1996) Laboratory-clinic interface: mechanisms of action of antiestrogens. Cancer Treat. Rev., 21, 247-271.
51. Wolf.D.M. and Jordan.V.C. (1993) Drug resistance to tamoxifen during breast cancer therapy. Breast Cancer Res. Treat., 27, 27-40.